13,14-DIHYDRO-15-KETO PROSTAGLANDIN E1-D4

13,14-DIHYDRO-15-KETO PROSTAGLANDIN E1-D4 Property

solubility 

DMF: 50 mg/ml
DMSO: 50 mg/ml
Ethanol: 50 mg/mlPBS: 1 mg/ml

Hazard and Precautionary Statements (GHS)

13,14-DIHYDRO-15-KETO PROSTAGLANDIN E1-D4 Chemical Properties,Usage,Production

Description

13,14-dihydro-15-keto Prostaglandin E1-d4 (13,14-dh-15-k PGE1-d4) is intended for use as an internal standard for the quantification of 13,14-dh-15-k PGE1 by GC- or LC-mass spectrometry. 13,14-dh-15-k PGE1 is a metabolite of PGE1 with much reduced biological activity.1,2,3 Steady state plasma concentrations are about 10 pg/ml.1 13,14-dh-15-k PGE1 is a weak inhibitor of ADP-induced platelet aggregation in human PRP and washed platelets with IC50 values of 54 and 200 µM, respectively, compared to PGE1 which has an IC50 value of 40 nM.4WARNING This product is not for human or veterinary use.

References

[1] A LEONHARDT. In vivo formation of prostaglandin E1 and prostaglandin E2 in atopic dermatitis.[J]. British Journal of Dermatology, 1997, 136 3: 337-340.
[2] M. HAMBERG B S. On the Metabolism of Prostaglandins E1 and E2 in Man[J]. Journal of Biological Chemistry, 1971, 246 1: 6713-6721. DOI: 10.1016/s0021-9258(19)45905-x
[3] B A PESKAR. On the metabolism of prostaglandin E1 administered intravenously to human volunteers.[J]. Journal of Physiology and Pharmacology, 1991, 42 3: 327-331.
[4] I. JÄRVING. ANTIAGGREGATING POTENCY OF E-TYPE PROSTAGLANDINS IN HUMAN AND RABBIT PLATELETS[J]. Proceedings of the Estonian Academy of Sciences. Chemistry, 1991, 32 1. DOI: 10.3176/chem.1991.3.09